PSivida: Durasert Second Phase 3 Trial Meets Primary Efficacy Goal
- Author: Zachary Reyes Jun 17, 2017,
Jun 17, 2017, 13:31
The number of shares now held by investors is 39.36 Million. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/06/16/psivida-corp-psdv-stock-rating-reaffirmed-by-fbr-co-updated-updated-updated.html. Geode Capital Management LLC boosted its stake in shares of pSivida Corp.by 0.5% in the first quarter. Geode Capital Management LLC now owns 143,049 shares of the company's stock valued at $246,000 after buying an additional 756 shares in the last quarter. Renaissance Technologies LLC increased its stake in pSivida Corp.by 34.0% in the fourth quarter.
Durasert three-year insert demonstrated a significant reduction in the recurrence of posterior segment uveitis through six months, the company said. Vanguard Group Inc. increased its position in shares of pSivida Corp.by 3.5% in the first quarter. The company generates revenue of $1.43 Billion and has a net income of $-140.80 Million, for the trailing twelve months. (NASDAQ:PSDV) news were published by: Reuters.com which released: "BRIEF-Pfizer reports 4.7 pct stake in pSivida Corp as of May 15 - SEC filing" on May 26, 2017, also Seekingalpha.com with their article: "An Eye On Ophthalmology: Analyzing pSivida's Upcoming Clinical Trial" published on May 17, 2017, Globenewswire.com published: "pSivida Corp". Insiders own 2.59% of the company's stock.
pSivida Corp. (NASDAQ:PSDV) on Tuesday closed at $1.75. The firm has a 50-day moving average of $1.79 and a 200 day moving average of $1.80.
Currently, the market capitalization of pSivida Corp. Equities research analysts expect that pSivida Corp. will post ($0.51) EPS for the current fiscal year. Virginia-based Thompson Siegel & Walmsley Limited Liability Corporation has invested 0% in pSivida Corp. (NASDAQ:PSDV) for 205,400 shares. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & global copyright & trademark law. For the current quarter Psivida Corp Com (NASDAQ:PSDV) has high EPS estimates of $-0.12 in contradiction of low EPS estimates of $-0.17. Several analysts have commented on the company. HC Wainwright set a $8.00 target price on pSivida Corp. and gave the stock a "buy" rating in a research report on Wednesday. Therefore 100% are positive. pSivida had 3 analyst reports since October 15, 2015 according to SRatingsIntel.
02/21/2014 - pSivida Corp. was upgraded to "hold" by analysts at Jefferson Research. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. The lowest target is $6.0 while the high is $8. Given that liquidity is king in short-term, VALE is a stock with 5.01 billion shares outstanding that normally trades 2.88% of its float. A total of 6.04 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 486.33 Million shares, while its relative volume stands at 12.43. EPS breaks down the profitability of the company on a single share basis.
Watertown, MA-based pSivida says their lead eye drug for posterior segment uveitis hit the primary endpoint of their second Phase III trial, putting them on track to a European filing this month with an FDA application scheduled to arrive in Q4.